Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ribavirin therapeutic drug monitoring: why, when and how?
Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P; French Ribavirin Group OPTIRIB. Stanke-Labesque F, et al. Among authors: babany g. Fundam Clin Pharmacol. 2010 Aug;24(4):401-6. doi: 10.1111/j.1472-8206.2009.00778.x. Epub 2009 Sep 24. Fundam Clin Pharmacol. 2010. PMID: 19788564 Review.
Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.
Loustaud-Ratti V, Stanke-Labesque F, Marquet P, Gagnieu MC, Maynard M, Babany G, Trépo C; French Ribavirin Group OPTIRIB. Loustaud-Ratti V, et al. Among authors: babany g. Gastroenterol Clin Biol. 2009 Jun-Jul;33(6-7):580-3. doi: 10.1016/j.gcb.2009.04.009. Epub 2009 May 28. Gastroenterol Clin Biol. 2009. PMID: 19481390 Free article. No abstract available.
Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.
Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P. Sauvage FL, et al. Among authors: babany g. Ther Drug Monit. 2009 Jun;31(3):374-81. doi: 10.1097/FTD.0b013e3181a665e3. Ther Drug Monit. 2009. PMID: 19412142 Free PMC article.
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Loustaud-Ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, Trépo C, De Ledinghen V, Bourlière M, Pol S, Di Martino V, Zarski JP, Pinta A, Sautereau D, Marquet P; OPTIRIB group. Loustaud-Ratti V, et al. Among authors: babany g. Dig Liver Dis. 2011 Nov;43(11):850-5. doi: 10.1016/j.dld.2011.04.002. Epub 2011 May 18. Dig Liver Dis. 2011. PMID: 21596633 Review.
High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).
Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. Chevaliez S, et al. Among authors: babany g. Gastroenterology. 2011 Jul;141(1):119-27. doi: 10.1053/j.gastro.2011.03.039. Epub 2011 Mar 24. Gastroenterology. 2011. PMID: 21439960 Free article. Clinical Trial.
Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.
Calès P, Zarski JP, Chapplain JM, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop). Calès P, et al. Among authors: babany g. J Viral Hepat. 2012 Feb;19(2):e143-53. doi: 10.1111/j.1365-2893.2011.01531.x. Epub 2011 Oct 30. J Viral Hepat. 2012. PMID: 22239512
63 results